(ANIP) ANI Pharmaceuticals - Overview

Sector: Healthcare | Industry: Drug Manufacturers - Specialty & Generic | Exchange: NASDAQ (USA) | Market Cap: 1.881m USD | Total Return: 34.8% in 12m

Generic Drugs, Branded Pharmaceuticals, Injectables, Rare Disease Therapies
Total Rating 65
Safety 66
Buy Signal -0.91
Drug Manufacturers - Specialty & Generic
Industry Rotation: -4.2
Market Cap: 1.88B
Avg Turnover: 27.4M
Risk 3d forecast
Volatility36.4%
VaR 5th Pctl6.21%
VaR vs Median3.39%
Reward TTM
Sharpe Ratio0.89
Rel. Str. IBD40.9
Rel. Str. Peer Group44.8
Character TTM
Beta0.426
Beta Downside0.676
Hurst Exponent0.432
Drawdowns 3y
Max DD28.66%
CAGR/Max DD0.63
CAGR/Mean DD1.55
EPS (Earnings per Share) EPS (Earnings per Share) of ANIP over the last years for every Quarter: "2021-03": 1.04, "2021-06": 0.67, "2021-09": 1.01, "2021-12": 0.54, "2022-03": -0.12, "2022-06": 0.13, "2022-09": 0.64, "2022-12": 0.76, "2023-03": 1.17, "2023-06": 1.28, "2023-09": 1.27, "2023-12": 1, "2024-03": 1.21, "2024-06": 1.02, "2024-09": 1.34, "2024-12": -0.55, "2025-03": 1.7, "2025-06": 1.8, "2025-09": 1.13, "2025-12": 2.33, "2026-03": 2.05,
EPS CAGR: 12.34%
EPS Trend: 41.9%
Last SUE: 1.63
Qual. Beats: 1
Revenue Revenue of ANIP over the last years for every Quarter: 2021-03: 54.521, 2021-06: 48.625, 2021-09: 52.061, 2021-12: 60.929, 2022-03: 64.477, 2022-06: 73.855, 2022-09: 83.821, 2022-12: 94.232, 2023-03: 106.786, 2023-06: 116.547, 2023-09: 131.829, 2023-12: 131.654, 2024-03: 137.43, 2024-06: 138.04, 2024-09: 148.332, 2024-12: 190.574, 2025-03: 197.122, 2025-06: 211.371, 2025-09: 227.813, 2025-12: 247.06, 2026-03: 237.462,
Rev. CAGR: 35.21%
Rev. Trend: 99.4%
Last SUE: 4.00
Qual. Beats: 6

Warnings

Below Avwap Earnings

Tailwinds

Garp

Description: ANIP ANI Pharmaceuticals

ANI Pharmaceuticals, Inc. (NASDAQ: ANIP) is a biopharmaceutical firm integrated across the development, manufacturing, and commercialization of branded and generic medicines. Its portfolio includes complex formulations such as Cortrophin gel, injectables, and ophthalmology products like ILUVIEN and YUTIQ. The company utilizes a broad distribution network encompassing national wholesalers, specialty pharmacies, and healthcare providers.

The business model relies on a mix of high-barrier generic manufacturing and a growing branded specialty segment, which typically offers higher margins than standard commodity generics. Operating in the pharmaceutical sector requires significant capital investment in specialized facilities for controlled substances and potent compounds to meet stringent regulatory standards. Investors can explore detailed valuation metrics and peer comparisons on ValueRay to deepen their understanding of the companys market position.

Headquartered in Baudette, Minnesota, the company maintains internal capabilities for oral solid doses, semi-solids, and liquids. This vertical integration allows for greater control over the supply chain and production costs across its international markets.

Headlines to Watch Out For
  • Cortrophin Gel market share expansion drives high-margin specialty pharmaceutical revenue growth
  • Integration of Alimera Sciences portfolio accelerates ophthalmology segment sales and margins
  • Generic product pipeline execution mitigates pricing pressure in established portfolio segments
  • Increased manufacturing capacity at Baudette facility optimizes internal cost structures and margins
  • Regulatory approval timelines for new generic filings impact long-term revenue projections
Piotroski VR-10 (Strict) 7.0
Net Income: 89.7m TTM > 0 and > 6% of Revenue
FCF/TA: 0.12 > 0.02 and ΔFCF/TA 7.84 > 1.0
NWC/Revenue: 54.95% < 20% (prev 49.62%; Δ 5.33% < -1%)
CFO/TA 0.15 > 3% & CFO 208.6m > Net Income 89.7m
Net Debt (302.6m) to EBITDA (237.0m): 1.28 < 3
Current Ratio: 3.12 > 1.5 & < 3
Outstanding Shares: last quarter (21.5m) vs 12m ago 7.47% < -2%
Gross Margin: 65.94% > 18% (prev 0.59%; Δ 6.53k% > 0.5%)
Asset Turnover: 68.06% > 50% (prev 52.16%; Δ 15.90% > 0%)
Interest Coverage Ratio: 4.61 > 6 (EBITDA TTM 237.0m / Interest Expense TTM 32.0m)
Altman Z'' 3.10
A: 0.36 (Total Current Assets 747.1m - Total Current Liabilities 239.5m) / Total Assets 1.42b
B: 0.00 (Retained Earnings 6.39m / Total Assets 1.42b)
C: 0.11 (EBIT TTM 147.5m / Avg Total Assets 1.36b)
D: 0.01 (Book Value of Equity 6.88m / Total Liabilities 859.7m)
Altman-Z'' = 3.10 = A
Beneish M -3.19
DSRI: 0.85 (Receivables 255.4m/220.3m, Revenue 923.7m/674.1m)
GMI: 0.90 (GM 65.94% / 59.34%)
AQI: 0.79 (AQ_t 0.43 / AQ_t-1 0.54)
SGI: 1.37 (Revenue 923.7m / 674.1m)
TATA: -0.08 (NI 89.7m - CFO 208.6m) / TA 1.42b)
Beneish M = -3.19 (Cap -4..+1) = AA
What is the price of ANIP shares?

As of May 30, 2026, the stock is trading at USD 78.51 with a total of 415,708 shares traded.
Over the past week, the price has changed by -5.15%, over one month by +0.69%, over three months by +6.24% and over the past year by +34.76%.

Is ANIP a buy, sell or hold?

ANI Pharmaceuticals has received a consensus analysts rating of 4.33. Therefore, it is recommended to buy ANIP.

  • StrongBuy: 3
  • Buy: 2
  • Hold: 1
  • Sell: 0
  • StrongSell: 0

What are the forecasts/targets for the ANIP price?
Analysts Target Price 109.9 40%
ANI Pharmaceuticals (ANIP) - Fundamental Data Overview as of 26 May 2026
Market Cap USD = 1.88b (1.88b USD * 1.0 USD.USD)
P/E Trailing = 21.156
P/E Forward = 10.02
P/S = 2.0359
P/B = 3.3465
P/EG = 1.06
Revenue TTM = 923.7m USD
EBIT TTM = 147.5m USD
EBITDA TTM = 237.0m USD
Long Term Debt = 594.5m USD (from longTermDebt, last quarter)
Short Term Debt = 19.3m USD (from shortTermDebt, last quarter)
Debt = 613.8m USD (corrected: LT Debt 594.5m + ST Debt 19.3m)
Net Debt = 302.6m USD (calculated: Debt 613.8m - CCE 311.2m)
Enterprise Value = 2.18b USD (1.88b + Debt 613.8m - CCE 311.2m)
Interest Coverage Ratio = 4.61 (Ebit TTM 147.5m / Interest Expense TTM 32.0m)
EV/FCF = 13.18x (Enterprise Value 2.18b / FCF TTM 165.6m)
FCF Yield = 7.59% (FCF TTM 165.6m / Enterprise Value 2.18b)
FCF Margin = 17.93% (FCF TTM 165.6m / Revenue TTM 923.7m)
Net Margin = 9.71% (Net Income TTM 89.7m / Revenue TTM 923.7m)
Gross Margin = 65.94% ((Revenue TTM 923.7m - Cost of Revenue TTM 314.6m) / Revenue TTM)
Gross Margin QoQ = 51.78% (prev none%)
Tobins Q-Ratio = 1.54 (Enterprise Value 2.18b / Total Assets 1.42b)
Interest Expense / Debt = 5.22% (Interest Expense 32.0m / Debt 613.8m)
Taxrate = 26.68% (10.7m / 40.2m)
NOPAT = 108.2m (EBIT 147.5m * (1 - 26.68%))
Current Ratio = 3.12 (Total Current Assets 747.1m / Total Current Liabilities 239.5m)
Debt / Equity = 1.09 (Debt 613.8m / totalStockholderEquity, last quarter 562.3m)
Debt / EBITDA = 1.28 (Net Debt 302.6m / EBITDA 237.0m)
Debt / FCF = 1.83 (Net Debt 302.6m / FCF TTM 165.6m)
Total Stockholder Equity = 517.6m (last 4 quarters mean from totalStockholderEquity)
RoA = 6.61% (Net Income 89.7m / Total Assets 1.42b)
RoE = 17.32% (Net Income TTM 89.7m / Total Stockholder Equity 517.6m)
RoCE = 13.26% (EBIT 147.5m / Capital Employed (Equity 517.6m + L.T.Debt 594.5m))
RoIC = 9.55% (NOPAT 108.2m / Invested Capital 1.13b)
WACC = 6.58% (E(1.88b)/V(2.49b) * Re(7.48%) + D(613.8m)/V(2.49b) * Rd(5.22%) * (1-Tc(0.27)))
Discount Rate = 7.48% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 91.11 | Cagr: 5.21%
[DCF] Terminal Value 77.97% ; FCFF base≈119.0m ; Y1≈136.4m ; Y5≈200.8m
[DCF] Fair Price = 119.6 (EV 3.02b - Net Debt 302.6m = Equity 2.72b / Shares 22.7m; r=8.35% [WACC [floored]]; 5y FCF grow 15.0% → 2.50% )
EPS Correlation: 41.94 | EPS CAGR: 12.34% | SUE: 1.63 | # QB: 1
Revenue Correlation: 99.39 | Revenue CAGR: 35.21% | SUE: 4.0 | # QB: 6
EPS current Quarter (2026-06-30): EPS=2.00 | Chg30d=-8.17% | Revisions=-33% | Analysts=7
EPS next Quarter (2026-09-30): EPS=2.52 | Chg30d=+0.29% | Revisions=+11% | Analysts=7
EPS current Year (2026-12-31): EPS=9.40 | Chg30d=+3.55% | Revisions=+64% | GrowthEPS=+19.1% | GrowthRev=+27.1%
EPS next Year (2027-12-31): EPS=10.61 | Chg30d=+0.18% | Revisions=-27% | GrowthEPS=+12.9% | GrowthRev=+11.2%
[Analyst] Revisions Ratio: +64%